Formulation and evaluation of dexlansoprazole extended-release tablet

Shubham Santosh  Sharma; Pooja Ganesh  Bhutada

doi:10.30574/gscbps.2021.17.3.0352

Authors

Shubham Santosh Sharma Department of Quality Assurance, Vidyabharati College of Pharmacy, Amravati, (MH), Pin 444602 India.
Pooja Ganesh Bhutada Department of Quality Assurance, Vidyabharati College of Pharmacy, Amravati, (MH), Pin 444602 India.

DOI:

https://doi.org/10.30574/gscbps.2021.17.3.0352

Keywords:

Dexlansoprazole, Gastroesophageal reflux disease, Proton pump inhibitor, Sustain release tablet

Abstract

Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. Shellac can be used to develop the sustain release tablet of dexlansoprazole as retardation of the drug (dexlansoprazole) was observed in the acidic pH of the stomach, and hence a sustain coated dexlansoprazole tablet was prepared and evaluated. The coating's primary function is to allow for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits faster degradation in the acidic pH of the stomach, therefore increasing pharmacological action. DSP coating with different polymers inhibits fast degradation in the stomach's acidic pH, enhancing pharmacological action. The major function of the coating is to enable for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits fast breakdown in the stomach's acidic pH, enhancing pharmacological action.

Metrics

Metrics Loading ...

References

Peura D. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009; 117.

Shyam Sundar Rao K, Mishra V, Nayak M, Scholar R, Professor -Asst. Pelletization technology in pharmaceutical formulation. Int J Adv Pharm Sci [Internet]. 1 January 2019; 12.

Kamboj S, Chopra S. Quality by design (QBD) in pharmaceutical industry. Int J Curr Pharm Rev Res. 2015; 6(2): 142–8.

Grady H, Murakawa Y, Mulford D, Kukulka M. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor. J Pharm Sci [Internet]. 2019; 108(11): 3496–501.

Om Anand,corresponding author Lawrence X. Yu, Dale P. Conner and BMD. Dissolution Testing for Generic Drugs: An FDA Perspective. AAPS J [Internet]. 2011; 13(3): 328.

Paul DR. Elaborations on the Higuchi model for drug delivery. Int J Pharm [Internet]. 2011; 418(1): 13–7.